369 related articles for article (PubMed ID: 25445343)
1. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.
Chusri P; Kumthip K; Pantip C; Thongsawat S; O'Brien A; Maneekarn N
Virus Res; 2015 Jan; 196():37-43. PubMed ID: 25445343
[TBL] [Abstract][Full Text] [Related]
2. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
[TBL] [Abstract][Full Text] [Related]
3. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
[TBL] [Abstract][Full Text] [Related]
4. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
[TBL] [Abstract][Full Text] [Related]
6. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L
Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067
[TBL] [Abstract][Full Text] [Related]
7. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
[TBL] [Abstract][Full Text] [Related]
8. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
Zeuzem S; Lee JH; Roth WK
Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.
Provazzi PJ; Mukherjee S; Hanson AM; Nogueira ML; Carneiro BM; Frick DN; Rahal P
PLoS One; 2015; 10(12):e0144638. PubMed ID: 26658750
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
12. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Franco S; Clotet B; Martínez MA
Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
[TBL] [Abstract][Full Text] [Related]
13. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus.
Holland-Staley CA; Kovari LC; Golenberg EM; Pobursky KJ; Mayers DL
Arch Virol; 2002 Jul; 147(7):1385-406. PubMed ID: 12111414
[TBL] [Abstract][Full Text] [Related]
14. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.
Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; Elhefnawi M; Zaid A; Al-Qahtani AA
J Med Virol; 2014 Feb; 86(2):224-34. PubMed ID: 24166351
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
[TBL] [Abstract][Full Text] [Related]
17. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
[TBL] [Abstract][Full Text] [Related]
18. Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.
Fatima K; Tahir M; Qadri I
Virus Res; 2011 Sep; 160(1-2):230-7. PubMed ID: 21756947
[TBL] [Abstract][Full Text] [Related]
19. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
